2006 Volume 1 Issue 2 Pages 2_24-2_29
Objective: The purpose of this study was to evaluate the efficacy of risedronate for the improvement of the quality of life (QOL) in patients with primary osteoporosis.
Methods: Twenty-seven Japanese patients who had receutly been diagnosed with primary osteoporosis (mean age: 73.8 ± 9.1yr, 18 men and 9 women) were the subjects of this study. Using the Japan Osteoporosis Society Quality of Life Questionnaire (JOQOL), each patient's QOL was evaluated before treatment with oral risedronate 2.5mg once daily, and 3, 6, and 12 months during treatment. We also measured the bone mineral density (BMD), serum bone-specific alkaline phosphatase (BAP), and serum N-terminal telopeptide of type I collagen (NTx) before treatment and at 6 and 12 months.
Results: The JOQOL total score gradually increased and significantly improved after 12 months of treatment in both male (p=0.026) and female patient groups (p=0.021). The pain scores in the female group first improved significantly at 3 months (p=0.018) and continued to improve over the remaining 9 months of the study, while improvement in the male group reached a significant level at 12 months (p=0.048). Along with the improved pain scores, the other five scores (assessment of activities of daily living, entertainment and social activity, overall health, posture, and falls and anxiety) also tended to improve. Although risedronate did not significantly improve the BMD over the 12 months of this study, the serum BAP levels decreased over the 12 months period and significantly decreased in male (p=0.004) and female groups (p<0.001) at 6 months. The serum NTx level also decreased significantly in male (p=0.003) and female groups (p=0.046) at 12 months.
Conclusion: The administration of risedronate for 12 months significantly improved the QOL in patients with primary osteoporosis and resulted in improved bone metabolism. The JOQOL may be an efficacious index for judging the outcome of osteoporosis treatment.